Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Percy Ivy

Showing results (221-230 of 232) with videos related to

Pageof 24
Sort By:
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
JCO Precision Oncology|October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol TAnne S Tsao, Zihe Song, Alan L Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2023
The New NCI Precision Medicine TrialsLyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
BMJ (Clinical Research Ed.)|October 20, 2023
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidanceChristina Yap, Olga Solovyeva, Johann de Bono, et al.
BMJ (Clinical Research Ed.)|October 20, 2023
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidanceChristina Yap, Jan Rekowski, Moreno Ursino, et al.
Cancer Chemotherapy and Pharmacology|April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancerJulia Manzo, Shannon Puhalla, Shalu Pahuja, et al.
Eclinicalmedicine|January 29, 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trialsJan Rekowski, Christina Guo, Olga Solovyeva, et al.
Eclinicalmedicine|January 29, 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocolsMoreno Ursino, Guillermo Villacampa, Jan Rekowski, et al.
Journal of the National Cancer Institute|April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot StudyBarbara A Conley, Lou Staudt, Naoko Takebe, et al.
The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
Pageof 24

Showing results (221-230 of 232) with videos related to

Sort By:
Pageof 24
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
JCO Precision Oncology|October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol TAnne S Tsao, Zihe Song, Alan L Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2023
The New NCI Precision Medicine TrialsLyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
BMJ (Clinical Research Ed.)|October 20, 2023
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidanceChristina Yap, Olga Solovyeva, Johann de Bono, et al.
BMJ (Clinical Research Ed.)|October 20, 2023
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidanceChristina Yap, Jan Rekowski, Moreno Ursino, et al.
Cancer Chemotherapy and Pharmacology|April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancerJulia Manzo, Shannon Puhalla, Shalu Pahuja, et al.
Eclinicalmedicine|January 29, 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trialsJan Rekowski, Christina Guo, Olga Solovyeva, et al.
Eclinicalmedicine|January 29, 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocolsMoreno Ursino, Guillermo Villacampa, Jan Rekowski, et al.
Journal of the National Cancer Institute|April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot StudyBarbara A Conley, Lou Staudt, Naoko Takebe, et al.
The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
Pageof 24